NateraNTRA
Diagnostics · NASDAQ · USA
$390.79
Down 1.2% todayClose
Up 72.7% this year and +49.2% since June 26, ahead of the life science sector at +10.7%. Natera supplies 1 mapped company and buys from 1.
About Natera
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Theme exposure
Products
- Prenatal screening (Panorama)
- Oncology testing (Signatera)
- Transplant diagnostics
Competitors
- Guardant Health
- Exact Sciences
- Myriad Genetics
Risks
- Reimbursement & coverage
- Patent disputes
Same segment: Diagnostics
Tests, imaging and assays that support clinical decision-making. Segment 6 of 8 in the Medicine, pharma & life science value chain.
Compare NTRA
Side by side with the largest companies in the same segment.
See where Natera sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.
Open the Life science value chain →